Althea Group Holdings Ltd (ASX: AGH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Althea Group Holdings Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$73.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Shares Outstanding
312.43 million
Earnings per share
-0.061
Dividend per share
N/A
Year To Date Return
4.44%
Earnings Yield
N/A
Franking
N/A
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Althea Group Holdings Ltd (ASX: AGH)
Latest News
Cannabis Shares
Here’s why the Althea (ASX:AGH) share price is rocketing 12% today
Cannabis Shares
These were the best performing ASX cannabis shares in October
Share Gainers
Beaten up ASX cannabis shares showing signs of life
Cannabis Shares
Althea (ASX:AGH) share price jumps 9% on cannabis drinks news
Share Market News
Why the Althea (ASX:AGH) share price is sinking 10% today
Share Gainers
Why Althea, Audinate, Perenti, & Viva Energy shares are pushing higher
Cannabis Shares
Why the Althea (ASX:AGH) share price is charging higher today
Cannabis Shares
Blazing it? How the top ASX cannabis shares performed in FY21
Frequently Asked Questions
-
Althea Group does not currently pay a dividend.
-
No, Althea Group doesn’t currently offer a dividend reinvestment plan (DRP).
AGH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Althea Group Holdings Ltd
One of Australia’s ASX cannabis shares, Althea Group Holdings Limited (ASX: AGH) cultivates, produces, supplies, imports, and exports pharmaceutical grade medicinal cannabis in Australia and the United Kingdom.
Althea also offers a range of education, access and management services to support eligible patients and healthcare professionals in navigating medicinal cannabis treatment pathways.
Althea shares first listed on the ASX in September 2018. The AGH share price is tied to the global legal marijuana market, which has been spurred by increased legalisation and the use of marijuana in medical applications.
AGH Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 21 Jan 2022 | $0.24 | $0.00 | 0.00% | 500,888 | $0.23 | $0.24 | $0.23 |
| 20 Jan 2022 | $0.24 | $0.03 | 14.29% | 585,258 | $0.23 | $0.24 | $0.22 |
| 19 Jan 2022 | $0.21 | $-0.01 | -4.65% | 376,474 | $0.22 | $0.22 | $0.21 |
| 18 Jan 2022 | $0.22 | $0.00 | 0.00% | 184,794 | $0.22 | $0.22 | $0.22 |
| 17 Jan 2022 | $0.22 | $-0.01 | -4.55% | 89,079 | $0.22 | $0.23 | $0.22 |
| 14 Jan 2022 | $0.22 | $0.00 | 0.00% | 175,799 | $0.22 | $0.22 | $0.22 |
| 13 Jan 2022 | $0.22 | $0.00 | 0.00% | 222,640 | $0.22 | $0.22 | $0.22 |
| 12 Jan 2022 | $0.22 | $0.01 | 4.65% | 169,146 | $0.22 | $0.23 | $0.22 |
| 11 Jan 2022 | $0.22 | $-0.01 | -4.44% | 41,012 | $0.22 | $0.22 | $0.22 |
| 10 Jan 2022 | $0.23 | $0.00 | 0.00% | 106,268 | $0.23 | $0.23 | $0.22 |
| 07 Jan 2022 | $0.23 | $0.01 | 4.55% | 39,932 | $0.22 | $0.23 | $0.22 |
| 06 Jan 2022 | $0.22 | $-0.01 | -4.35% | 542,194 | $0.23 | $0.24 | $0.22 |
| 05 Jan 2022 | $0.23 | $0.01 | 4.44% | 92,003 | $0.23 | $0.23 | $0.23 |
| 04 Jan 2022 | $0.23 | $0.00 | 0.00% | 199,851 | $0.23 | $0.24 | $0.22 |
| 31 Dec 2021 | $0.23 | $-0.01 | -4.35% | 45,382 | $0.23 | $0.23 | $0.22 |
| 30 Dec 2021 | $0.23 | $0.00 | 0.00% | 176,728 | $0.23 | $0.23 | $0.23 |
| 29 Dec 2021 | $0.24 | $0.00 | 0.00% | 29,050 | $0.23 | $0.24 | $0.23 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 27 Jan 2021 | Alan Boyd | Buy | 68 | $30,000 |
Participation in share purchase plan.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Alan Maclean Boyd | Non-Executive Director | Jun 2018 |
Mr Boyd was the Chief Financial Officer of Ridley Corporation Limited, an ASX-listed provider of high performance animal nutrition solutions. Prior to his role, Mr Boyd occupied the Chief Financial Officer and Company Secretary position with listed biotechnology companies Avexa Limited and Zenyth Therapeutics Limited and website pioneer Sausage Software Limited. Mr Boyd started his professional career in chartered accounting firms in England and Australia and has broad financial experience across many industry sectors. He is Chair of Audit, Risk and Compliance Management Committee and member of Remuneration and Nomination Committee
|
| Mr Philip Andrew Newbold | Non-Executive ChairmanNon-Executive Director | Jun 2018 |
Mr Newbold is a qualified lawyer having practised for nearly 20 years at a large commercial firm. Following his retirement from law in 2006, he founded a renewable energy business which he sold to Origin Energy in 2009. Since that time he has been involved in a start-up property app business which he sold to ANZ in 2015 and various other businesses. Mr Newbold has been a director of numerous private companies and not-for-profit organisations and currently is a director of Supra Capital, a Commissioner of the AFL and Chairman of Golf Australia. He is a Member of Audit, Risk and Compliance Management Committee & Remuneration and Nomination Committee
|
| Mr Joshua Michael Fegan | Chief Executive OfficerManaging Director | Jun 2018 |
Mr Fegan is the founder of Althea Group Holdings Limited and has experience in business building, sales and marketing. He has a range of business and strategy skills and has previously held a number of senior management roles at national value-based retailer, Strathfield Group. Mr Fegan founded Althea Health and Wellbeing in 2016, coinciding with registration of the Narcotic Drugs Amendment Act 2016 (Cth) (ND Amendment Act), an Act to amend the Narcotic Drugs Act 1967 (Cth) (ND Act), legalising medicinal cannabis
|
| Penelope Dobson | Non-Executive Director | Nov 2018 |
Mr Dobson is an experienced global healthcare executive. She has worked in the broad life-science space since her training as a pharmacist in New Zealand, including many years in the global pharmaceutical industry. Mr Dobson is currently a Principal at Valida Consulting, offering a range of services to companies in the healthcare, Pharma, Biotech, not-forprofit, Device and Diagnostics sector. She is Chair of Remuneration and Nomination Committee and member of Audit, Risk and Compliance Management Committee
|
| Mr Robert Meissner | Chief Financial OfficerCompany Secretary | Apr 2019 |
-
|
| Robert Meissner | Chief Financial OfficerCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Joshua Michael Fegan | 56,250,000 | 21.44% |
| Hsbc Custody Nominees (Australia) Limited | 16,016,253 | 6.10% |
| National Nominees Limited | 12,015,231 | 4.58% |
| Mancann Pty Ltd | 10,000,000 | 3.81% |
| J P Morgan Nominees Australia Pty Limited | 8,734,586 | 3.33% |
| Hootch Pty Ltd | 7,500,000 | 2.86% |
| Oh-Rule Pty Ltd | 4,763,165 | 1.82% |
| Citicorp Nominees Pty Limited | 3,225,545 | 1.23% |
| Jamplat Pty Ltd | 2,390,000 | 0.91% |
| Pac Partners Securities Pty Ltd | 2,249,255 | 0.86% |
| Mr Hoang Huy Nguyen | 2,214,161 | 0.84% |
| Mr Philip John Cawood | 1,950,000 | 0.74% |
| BNP Paribas Nominees Pty Ltd | 1,775,000 | 0.68% |
| Maelstrom Pty Ltd (Falkiner Super Fund A/C) | 1,500,000 | 0.57% |
| Newbold Family Super Fund | 1,500,000 | 0.57% |
| Mansfield Can Investments Pty Ltd (Mansfield Super Fund A/C) | 1,366,035 | 0.52% |
| PAC Partners Pty Ltd | 1,017,347 | 0.39% |
| Mr Anthony Karl Stani | 850,000 | 0.32% |
| Emerging Equities Pty Ltd | 822,300 | 0.31% |
| BNP Paribas Nominees Pty Ltd I | 802,502 | 0.31% |